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OPEN
ORIGINAL ARTICLE
Dissection of major depressive disorder using polygenic risk
scores for schizophrenia in two independent cohorts
HC Whalley1, MJ Adams1, LS Hall1, T-K Clarke1, AM Fernandez-Pujals1, J Gibson1, E Wigmore1, J Hafferty1, SP Hagenaars1, G Davies2,3,
A Campbell4, C Hayward5, SM Lawrie1, DJ Porteous4, IJ Deary2,3 and AM McIntosh1,2
Major depressive disorder (MDD) is known for its substantial clinical and suspected causal heterogeneity. It is characterized by low
mood, psychomotor slowing and increased levels of the personality trait neuroticism; factors also associated with schizophrenia
(SCZ). It is possible that some cases of MDD may have a substantial genetic loading for SCZ. The presence of SCZ-like MDD
subgroups would be indicated by an interaction between MDD status and polygenic risk of SCZ on cognitive, personality and mood
measures. Here, we hypothesized that higher SCZ polygenic risk would define larger MDD case–control differences in cognitive
ability, and smaller differences in distress and neuroticism. Polygenic risk scores (PRSs) for SCZ and their association with cognitive
variables, neuroticism, mood and psychological distress were estimated in a large population-based cohort (Generation Scotland:
Scottish Family Health Study, GS:SFHS). The individuals were divided into those with, and without, depression (n = 2587 and
n= 16 764, respectively) to test for the interactions between MDD status and schizophrenia risk. Replication was sought in UK
Biobank (UKB; n= 6049 and n= 27 476 cases and controls, respectively). In both the cohorts, we found significant interactions
between SCZ-PRS and MDD status for measures of psychological distress (βGS =− 0.04, PGS = 0.014 and βUKB =− 0.09, PUKB⩽ 0.001 for
GS:SFHS and UKB, respectively) and neuroticism (βGS =− 0.04, PGS = 0.002 and βUKB =− 0.06, PUKB = 0.023). In both the cohorts, there
was a reduction of case–control differences on a background of higher genetic risk of SCZ. These findings suggest that depression
on a background of high genetic risk for SCZ may show attenuated associations with distress and neuroticism. This may represent a
causally distinct form of MDD more closely related to SCZ.
Translational Psychiatry (2016) 6, e938; doi:10.1038/tp.2016.207; published online 1 November 2016
INTRODUCTION
Major depressive disorder (MDD) has a lifetime prevalence of
approximately 16% and is a heritable and severely disabling
psychiatric condition.1 It is highly clinically heterogeneous, relying
on diagnostic criteria that are fulfilled through the presence of
an arbitrary threshold of symptoms that lack empirical validation.
Further, individuals passing this threshold can have a very
different combination of symptoms. As a likely consequence of
causal heterogeneity, the progress in our understanding of
depression’s underlying risk factors and biological mechanisms
has been limited.
MDD is characterized by sustained negative affect, psychologi-
cal distress and by differences in personality and behavioural
traits, such as increased levels of the personality trait neuroticism.2
People with MDD also manifest, on average, reduced executive
function, attention, processing speed and working memory,3 but
relatively preserved general cognitive ability.4 These behavioural
and personality features are partly heritable, enduring features of
illness that are often genetically correlated with liability to MDD.5–
8 Notably however, these clinical and personality associations are
not specific to MDD and also occur in other psychiatric disorders
including schizophrenia (SCZ).9–11
Although MDD is a notoriously heterogeneous disorder,
evidence is beginning to emerge to suggest potentially distin-
guishable aetiological sub-categories.12 For example, heritability
estimates are considerably higher for early-onset cases (⩽25 years)
in comparison with later-onset MDD.13 Early-onset MDD has also
been associated with a more malignant form of the disorder, with
increased numbers of episodes, greater symptom severity,
increased functional and behavioural impairments, and person-
ality traits such as increased neuroticism.14,15 Genetic studies also
suggest there may be differential pathways underlying these sub-
categories grouped according to the age of onset16,17 or symptom
profiles.12
Genetic factors account for ~ 37% of liability to MDD and
depressive symptoms.18,19 Genome-wide association studies have
indicated that ~ 30% of the heritability for MDD is accounted for
by an additive polygenic genetic architecture, where risk is
conferred by an accumulation of many alleles of small effect.20
Molecular genetic approaches also demonstrate shared genetic
architectures across the disorders.21 For example, two papers have
shown genetic correlation between MDD and SCZ using both
genome-wide association analysis identifying shared risk loci,21 or
an approach estimating genetic correlation from sampled single-
nucleotide polymorphisms (SNPs).22 These findings have been
interpreted as showing that there are genetic variants that raise
liability to both MDD and SCZ. Recently, however, a second
possibility has been proposed—that the genetic correlation
between SCZ and MDD is caused not by pleiotropy, but by the
misclassification of SCZ cases as MDD. This possibility has recently
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been tested using a novel method aimed at using genotype data
to distinguish pleiotropy from heterogeneity, where early
evidence suggested that some cases of SCZ may have been
misclassified as MDD, though this did not reach significance in this
proof of technique study.23 If confirmed, this would imply that
some cases of MDD would be a hidden ‘forme fruste’ of SCZ, or
that some individuals with MDD may be on a trajectory towards
SCZ, but have yet to manifest the clinical phenotype.
The effects of polygenic risk for SCZ have also been
demonstrated on a number of related behavioural and cognitive
phenotypes. It has been consistently demonstrated, for example,
that polygenic risk for schizophrenia is associated with decreased
cognitive ability in healthy control samples.24–27 However, as most
studies have examined these relationships in unaffected controls,
it is unclear whether the associations between SCZ risk and
behaviour/cognitive ability are ameliorated or magnified by the
presence of depression. Clarifying this relationship is important
because, if MDD consists of a subtype that is closely related to
schizophrenia, then that subtype would be expected to show
associations with behaviour and cognitive ability that resembled
those of SCZ itself.
In the current paper, we sought to stratify depression using a
continuous scale of SCZ polygenic risk score (PRS), hypothesizing
that case–control differences would depend on the genetic risk for
schizophrenia; in other words, that there would be a significant
interaction between SCZ-PRS and MDD status. We made two
predictions: (1) based on the premise that deficits in cognition are
greater in SCZ than in MDD, we first predicted that the high SCZ-
PRS and MDD case–control differences for cognitive variables
would be greater compared with those with lower SCZ PRS scores;
(2) as neuroticism and psychological distress differ to a greater
extent in MDD than SCZ,28 we also predicted that SCZ-PRS and
MDD status interactions would be found for these variables, but
that they would be the reverse direction to cognition (attenuated
in those with high SCZ PRS). We sought to test these predictions
in a population-based cohort study, the Generation Scotland
cohort: The Scottish Family Health Study sample (GS:SFHS).29,30




Generation Scotland: the Scottish Family Health Study. GS:SFHS is a family-
and population-based cohort study. The individuals were recruited at
random through general medical practices across Scotland. Initial data
collection for GS:SFHS took place between February 2006 and March 2011.
The complete study protocol has been described in detail elsewhere.29–31
Details of the mental health and related assessments are summarized
below. Ethical approval was provided by NHS Tayside Research Ethics
Committee (reference 05/S1401/89). Written consent for the use of data
was obtained from all the participants.
The full cohort consists of 23 690 individuals who were over 18 years at
the time of recruitment and 21 516 of these attended the research clinic.
The present study includes 19 351 individuals on whom genome-wide
genotype data were available (demographic details presented in Table 1).
Pedigree information was available for all the participants, and this has
subsequently been validated against estimates of relatedness estimated
using genome-wide SNP data on 19 995 individuals.
Assessment of MDD in GS:SFHS. MDD was diagnosed using the structured
clinical interview for the Diagnostic and Statistical Manual of Mental
Disorders (SCID).32 A brief questionnaire was administered to the
participants to screen for MDD. The participants were asked ‘Have you
ever seen anybody for emotional or psychiatric problems?’ and ‘Was there
ever a time when you, or someone else, thought you should see someone
because of the way you were feeling or acting?’ If they answered yes to
either of these questions (21.7% screened positive), they were asked to
complete the SCID.32 If they answered no to both of these questions, they
were assigned control status. Those who completed the SCID but did not
meet the criteria for MDD or other major psychiatric disorder were also
defined as controls. The individuals who declined to complete the
screening questionnaire or the SCID had their MDD status set to missing.
The individuals with a diagnosis of bipolar disorder were removed for the
purposes of the current investigation.
Cognitive assessment in GS:SFHS. The cognitive abilities were assessed
using four tests. Immediate and delayed scores from the recall section of
one story of the Wechsler Logical Memory III UK test were summed to
provide a measure of verbal declarative memory.33 The Wechsler Digit
Symbol Coding test was used to measure processing speed.33 The verbal
ability was assessed using the Mill Hill Vocabulary Scale, junior and senior
synonyms.34 The executive function was measured using the letter-based
phonemic verbal fluency test (letters C, F and L, for 1 min each).35 All the
test scores were scaled to a mean of zero and standard deviation of one.
Table 1. Demographics, clinical, behavioural and temperament measures for GS:SFHS individuals in the current study
Controls (n= 16 764)a MDD cases (n=2587)a Significance T/Chi2 (P-value)
Mean s.d. Mean s.d.
Demographics
Mean age (years)a 47.61 15.27 46.36 12.88 15.73 (7.31 × 10− 5)
Gender (M:F)a 7218:9546 — 746:1841 — 186.54 (2.20 × 10− 16)
Cognitive
Logical memory (n= 16 764;n= 2587) 30.70 8.48 31.16 7.89 9.16 (2.48 × 10− 3)
Digit symbol (n= 16 566;n= 2566) 72.32 17.32 71.59 16.21 1.47 (2.25 × 10− 1)
Mill Hill vocabulary (n= 16 456;n= 2563) 30.11 4.72 31.21 4.793 1.70 (1.92 × 10−1)
Verbal fluency (n= 16 553;n= 2575) 39.62 11.67 40.40 11.91 13.53 (2.35 × 10− 4)
Clinical and trait-related features
Psycholog distress (GHQ) 14.93 7.55 22.70a 12.62 1797.00 (o1.00 × 10− 100)
Neuroticism 3.46 2.94 6.46a 3.32 2155 (o1.00 × 10− 100)
PRS measure (measures scaled)
SCZ − 0.02 1.00 0.10 1.02 24.00 (9.69 × 10− 7)
Abbreviations: GHQ, General Health Questionnaire; GS:SFHS, Generation Scotland: Scottish Family Health Study; MDD, major depressive disorder; PRS,
polygenic risk score; SCZ, schizophrenia. aSample size as indicated unless otherwise specified in descriptive variable column, numbers for controls and MDD,
respectively. Controlled for age, sex, four-multidimensional scaling ancestry components and relatedness.
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General cognitive ability (g) scores were obtained by conducting principal
component analysis of the tests, and saving the scores on the first
unrotated principal component, on which all the tests had substantial
loadings.36
Measures of neuroticism and psychological distress GS:SFHS. Measures of
psychological distress were assessed using the 28-item General Health
Questionnaire (GHQ-28),37 which consists of four subscales designed to
assess the following: (1) somatic symptoms, (2) anxiety and insomnia, (3)
social dysfunction and (d) ‘severe depression’. A single measure of global
affective symptoms was derived from item responses, and the standard
Likert scoring totals were used in the current study. The Eysenck
Personality Questionnaire-Revised Short Form provided a measure of
neuroticism.38 For the numbers of individuals completing each measure,
see Table 2.
Genotyping and polygenic profiling in GS:SFHS. The blood samples were
collected using standard operating procedures and stored at the Wellcome
Trust Clinical Research Facility Genetics Core, Edinburgh (www.wtcrf.ed.ac.uk)
where they were genotyped using the IlluminaHumanOmniExpressExome-
8v1.0 BeadChip and Infinium chemistry.39 The genotypes were then
processed using the IlluminaGenomeStudio Analysis software v2011.1. The
details of blood collection and DNA extraction are provided elsewhere.40
The PRSs were calculated using the method described previously,41
using summary data from the most recent genome-wide association
studies from the Psychiatric Genomics Consortium (2014). Briefly, the SNPs
were excluded if they had a minor allele frequency o1%, deviated
significantly from Hardy–Weinberg equilibrium (Po1 × 10− 6) in the total
sample of founder individuals, or had a call rate o99%. Clump-based
linkage disequilibrium pruning (r2 = 0.2, 300 kb window) was performed to
create a SNP set in linkage equilibrium. Before creating PRSs, all strand-
ambiguous SNPs were removed from the GS:SFHS data set and the PRS for
each individual was calculated using the cumulative sum of the number of
each SNP allele multiplied by the log of the odds ratio for SCZ across their
whole genome. Five SNP set scores were generated using the P-value
threshold cut-offs of 1, 0.5, 0.1, 0.05 and 0.01. Our primary analyses concerned
those SNPs from the Psychiatric Genomics Consortium data that met a
significance level of P=0.5 consistent with the previous studies.41 The findings
for other thresholds are contained within the Supplementary Material.
Replication sample: UKB
This study includes replication data from the UKB Study (http://www.
ukbiobank.ac.uk). UKB received ethical approval from the Research Ethics
Committee (REC, reference: 11/NW/0382). UKB is a health research
resource that aims to improve the prevention, diagnosis and treatment
of a range of illnesses. Through UKB, 502 655 community-dwelling
participants were recruited between 2006 and 2010 in the United
Kingdom.42 They underwent cognitive, neuroticism and physical assess-
ments, provided blood, urine and saliva samples for future analysis, gave
detailed information about their backgrounds and lifestyles, and agreed to
have their health followed longitudinally. For the present study, genome-
wide genotyping data were available on 33 525 individuals. This data set
comprised individuals who survived the quality control process, were
independent of individuals within GS:SFHS, who were unrelated and who
did not meet criteria for another major psychiatric disorder. The individuals
were assigned to a narrow definition of MDD including cases of moderate
or recurrent MDD, (n= 6049 and n= 27 476 cases and controls, respec-
tively), see Supplementary Material for further information.
Cognitive assessment in UKB
Three cognitive tests were used in the present study to generate measures
of general intelligence ‘g’. These tests, which cover the cognitive domains
of reaction time, memory and verbal-numerical reasoning were collected
at the baseline assessment. In addition, the data from a second
assessment, which provided measures of processing speed (similar to
the Digit Symbol Coding test, the Symbol Digit Substitution test) were also
assessed (further details in Supplementary Material). All the test scores
were scaled to a mean of zero and standard deviation of 1. General
cognitive ability (g) was estimated using the principal component analysis
approach described above.36
Measures of neuroticism and psychological distress in UKB
In UKB, the participants completed the Neuroticism scale of the Eysenck
Personality Questionnaire-Revised Short Form (EPQ-R Short Form).43 As a
measure of psychological distress, UKB participants undertook the
Patient Health Questionnaire, which is a multipurpose instrument for
screening, diagnosing, monitoring and measuring the severity of depres-
sion. As in GS:SFHS, the scores were scaled to a mean of zero and standard
deviation of 1.
Genotyping and polygenic profiling in UKB
The details of the array design, genotyping, quality control and imputation
have been described previously.44 Quality control included removal of
participants based on missingness, relatedness, gender mismatch and non-
British ancestry. Polygenic profiles were created for SCZ in all the
genotyped participants using PRSice.45 PRSice calculates the sum of alleles
associated with the phenotype of interest across many genetic loci,
Table 2. PRSs SCZ×MDD status interactions in both samples
GS:SFHS
(Controls n= 16 764, MDD n= 2587)a
UK Biobank
(Controls n= 27 476, MDD n= 6049)a
Statistics (β) P-value Statistics (β) P-value
Cognitive
Composite 'g' factor − 0.0220 2.67× 10−1 Composite 'g' factor − 0.0434 1.75 × 10− 1
Logical memory
(n= 16 764; n= 2587)
− 0.0028 8.65× 10− 1 Memory − 0.0290 3.54 × 10− 1
Digit symbol
(n= 16 566; n= 2566)
−0.0313 4.31×10−2 Symb digit substitution
(n= 7799; n= 1767)
0.0197 6.52 × 10− 1
Mill Hill vocabulary
(n= 16 456; n= 2563)
0.0009 9.49× 10− 1 Reaction time
(n= 27 299; n= 6008)
0.0119 6.45 × 10− 1
Verbal fluency
(n= 16 553; n= 2575)
− 0.0010 7.42× 10− 1 Verb-num reasoning
(n= 26 847; n= 5929)
− 0.0282 2.92 × 10− 1
Clinical and trait-related features
Psycholog distress (GHQ) −0.0402 1.44×10−2 Psycholog distress (PHQ)
(n= 26 581; n= 5969)
−0.0903 8.03×10−4
Neuroticism −0.0483 1.96×10−3 Neuroticism −0.0602 2.28×10−2
Abbreviations: GHQ, General Health Questionnaire; GS:SFHS, Generation Scotland: Scottish Family Health Study; MDD, major depressive disorder; PHQ, Patient
Health Questionnaire; PRS, polygenic risk score; SCZ, schizophrenia; symb, symbol; verb-num, verbal-numerical. aSample size as indicated unless otherwise
specified in descriptive variable column, numbers for controls and MDD, respectively. Controlled for age, sex, population stratification and relatedness.
Significant interactions are highlighted in bold.
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weighted by their effect sizes estimated from a genome-wide association
study of that phenotype in an independent sample. Before creating the
scores, the SNPs with a minor allele frequency o1% were removed and
clumping was used to obtain SNPs in linkage equilibrium with an r2o0.25
within a 200 bp window. Multiple scores were then created for each
phenotype containing SNPs selected according to the significance of their
association with the phenotype. The genome-wide association studies
summary data were used to create polygenic profiles for SCZ in the UKB
participants, at thresholds of Po0.01, Po0.05, Po0.1, Po0.5 and all
SNPs. As in the main GS:SFHS analysis, current results focus on Po0.5.
Statistical analysis
All the analyses were conducted in ASReml-R (www.vsni.co.uk/software/
asreml, version 3.0). The associations were examined between PRSs for SCZ
and cognition (cognitive factor 'g', and contributing tests), psychological
distress (GHQ total) and neuroticism (from the Eysenck personality
questionnaire) using mixed linear model association analysis in GS:SFHS.
Age, age2, sex, four-multidimensional scaling ancestry components and
polygenic profile scores were entered as fixed effects. As GS:SFHS is a
family-based study, to control for relatedness family structure was fitted as
a random effect by creating an inverse relationship matrix using pedigree
kinship information. SCZ-PRS and MDD status were entered as main effects
in the model and PRS×MDD status effects were examined by including
the interaction term. Where significant interactions were found, further
tests were conducted in controls and MDD groups separately. Wald’s
conditional F-test was used to calculate the significance of fixed effects.
The P-values presented are raw P-values uncorrected for multiple testing,
results were considered significant if they were reported in both the
cohorts (Po0.05). The reported β-values are standardized values. The
proportion of phenotypic variance explained by PRS was calculated by
multiplying the profile score by its corresponding regression coefficient
and estimating its variance. This value was then divided by the variance of
the observed phenotype to yield a coefficient of determination between 0
and 1 and converted into a percentage.46
Significant association and interaction effects were also explored within
the independent sample UKB where equivalent measures were available.
In UKB, the polygenic risk profile scores were examined for their
association with observed phenotypes and for group interaction effects
in ASReml-R using the same methods as above (details in Supplementary
Material), but without the inclusion of a genetic relationship matrix owing
to the large data set and unrelated nature of the filtered UKB study
population used in the current investigation.
RESULTS
Demographic, cognitive, trait-related features of MDD and PRS
scores in GS:SFHS
The demographic details are presented in Table 1 for GS:SFHS. The
groups defined according to depression status were significantly
different in terms of age, sex, for the cognitive measures of logical
memory and verbal fluency, with the greatest differences between
groups for measures of psychological distress (GHQ) and for
neuroticism (Table 1), higher in MDD cases. The MDD cases and
controls also differed significantly on the SCZ PRS score, with the
MDD individuals scoring higher.
The demographic details of the individuals from UKB included
in the current study are presented in Supplementary Table 1.
There were significant differences between the groups in terms of
age and gender. The groups also differed according to
psychological distress and neuroticism, with the MDD cases
scoring higher than controls. Differences between the groups did
not reach significance for the individual cognitive tests, and the
MDD cases and controls differed significantly on the SCZ PRS
score, with the MDD individuals scoring higher.
Interaction between MDD status and polygenic risk for
schizophrenia, in GS:SFHS and UKB
The results for tests of interaction are presented in Table 2 and
Figures 1a and b. Significant PRS SCZ×group interactions effects
were seen across both cohorts for measures of psychological
distress (βGS =− 0.0402, PGS = 1.44 × 10
− 2; βUKB =− 0.0903,
PUKB = 8.03 × 10
− 4, GS:SFHS and UKB, respectively, Figure 1) and
for neuroticism (βGS =− 0.0483, PGS = 1.96 × 10
− 3; βUKB =− 0.0602,
PUKB = 2.28 × 10
− 2). A significant interaction was also reported for
measures of processing speed in GS:SFHS (βGS =− 0.0313,
PGS = 4.31 × 10
− 2), but this was not replicated in the UKB sample.
In terms of the direction of associations within the diagnostic
groups, in both GS:SFHS and UKB samples, there was a significant
positive association in the control group for measures of
psychological distress (βGS = 0.0400, PGS = 1.46 × 10
− 8; βUKB =
0.0827, PUKB = 3.25 × 10
− 14) and for neuroticism (βGS = 0.0369,
PGS = 9.15 × 10
− 6; βUKB = 0.0539, PUKB = 4.79 × 10
− 19, GS:SFHS and
UKB; see Table 3). There were no significant associations within
the MDD groups for either measure, in either cohort (see Table 3,
Figures 1 a and b).
In terms of psychological distress, the proportion of variance
explained was 0.15 and 0.22% for control individuals, for GS:SFHS
and UKB, respectively, and 0.02%, 0.01% for MDD cases. For
measures of neuroticism, values were 0.17 and 0.30% in the
controls and o0.01% in the MDD cases (see Table 3 and Figure 2).
For both distress and neuroticism, the SCZ-PRS ×MDD status
interactions remained significant after modelling if the individuals
were experiencing a current depressive episode at the time of
assessment according to the SCID, and remained significant when
modelling if individuals were taking antidepressant medication at
the time of assessment according to self-report; full details in
Supplementary Material.
DISCUSSION
Consistent with our predictions, we report MDD case–control
differences in neuroticism and distress that were attenuated by
higher SCZ PRS scores, found in both the cohorts. We also
demonstrate that the greatest variance explained for neuroticism
and distress was higher in controls than in the MDD cases,
supporting the suggestion that the MDD samples contain a more
heterogeneous group comprising differing aetiological subtypes.
Although we also report larger MDD case–control differences with
respect to cognition in the context of higher SCZ PRS scores in GS:
SFHS, this was not replicated in the independent UKB cohort.
PRS SCZ associations and interactions with clinical and trait
features
Neuroticism is considered to be a stable heritable trait47
characterized by high tension, irritability, dissatisfaction, shyness,
low mood and reduced self-confidence.38 Psychological distress is
a more generalized measure of psychiatric well-being or
psychological health than a specific psychopathological categor-
ization. These two traits have been reported to share strong
genetic links,7 and there has been considerable support for
overlapping genetic risk factors affecting neuroticism and MDD.48
Direct links between genetic risk for schizophrenia and these
measures, however, are less commonly reported than associations
with cognitive deficits, as described above.
These measures demonstrated significant interaction effects
between SCZ-PRS and MDD case–control status, seen in both GS:
SFHS and UKB cohorts. From Figure 1, it can be seen that for
controls, neuroticism scores were positively correlated with SCZ
PRSs, which has indeed been previously reported.49 However, for
MDD cases, the regression line indicated that neuroticism scores
did not depend on PRS SCZ. Similar patterns were observed for
psychological distress. We are not aware of this relationship
having been reported previously. In addition, the variance
explained for these measures was greater in control individuals
(~0.20%) than in the MDD cases (~0.01%). We suggest that this
may be attributable to the aetiologically diverse subgroups within
the MDD cases. The origins of these interactions were an
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attenuation of case–control differences on a background of higher
genetic risk of SCZ, seen in both cohorts. Neuroticism and
psychological distress may therefore be less closely related to the
aetiology of depression in the context of high genetic risk for
schizophrenia (see Figure 1). It is, however, also possible that the
absence of a similar gradient of effect in the MDD cases could be
owing to the substantial effects of depression on distress and
neuroticism, leading to a ceiling effect whereby the additional
effect of SCZ PRS on these phenotypes is undetectable. However,
we consider that this is unlikely as the variance of these measures
are not in fact smaller in the MDD groups in comparison with the
control group (which would be the case if there were ceiling
effects, see Table 1), and so truncation of these scores at the
extreme end seems unlikely. Together, these findings suggest that
depression on a background of high genetic risk for schizophrenia
may represent a somewhat causally distinct form of the condition.
Figure 1. (a and b) Scatterplot of SCZ PRS and neuroticism according to MDD status in GS:SFHS, and UK Biobank (UKB), respectively. The size
of circles represents the degree of overlapping data points. For clarity, histograms of the distribution of neuroticism scores in cases and
controls for both cohorts are presented in the Supplementary Figures 1a and b. GS:SFHS, Generation Scotland: Scottish Family Health Study;
MDD, major depressive disorder; PRS, polygenic risk score (PGRS in the figure); SCZ, schizophrenia.
Stratifying depression by schizophrenia risk
HC Whalley et al
5
Translational Psychiatry (2016), 1 – 8
PRS SCZ associations and interactions with cognition
Previous studies have consistently reported a negative relation-
ship between cognitive function and SCZ PRS, indicating shared
genetic risk between SCZ and deficits in cognition.24–26,50 With the
exception of one previous study where genetic loading for SCZ
(based on proximal family history) was reported to have a
substantial negative impact on neurocognition in mood disorder
patients,51 we are not aware of any other studies examining this
relationship in the context of MDD. In the current study, the data
from the four individual subtests that contributed to the general
Table 3. Associations between PRSs for SCZ with cognitive, clinical and trait-related features of MDD in cases/controls separately
Generation Scotland: SFHS
Controls (n= 16 764) MDD cases (n= 2587)
β P-value R2 β P-value R2
Cognitive
Composite 'g' factor − 0.0773 2.61 × 10− 17 0.3470 − 0.0906 6.50 × 10− 5 0.6671
Logical memory − 0.0600 2.33 × 10− 13 0.3119 − 0.0764 3.00 × 10− 5 0.8353
Digit symbol −0.0654 3.27× 10−20 0.3258 −0.0906 7.35×10−8 1.0900
Mill Hill vocabulary − 0.0251 1.36× 10− 3 0.0379 − 0.0131 5.01 × 10− 1 0.0173
Verbal fluency − 0.0152 6.70× 10− 2 0.0190 − 0.0064 7.54 × 10− 1 0.0110
Clinical and trait-related features
Psycholog distress (GHQ) 0.0400 1.46×10−8 0.1487 0.0111 6.99×10−1 0.0149
Neuroticism 0.0369 91.15×10−6 0.1661 −0.0002 9.91×10−1 0.0009
UK Biobank
Controls (n= 27 476) MDD cases (n= 6049)
β; z ratio P-value R2 β; z ratio P-value R2
Cognitive
Composite 'g' factor − 0.1203 6.99× 10− 13 0.3156 − 0.1696 4.12 × 10− 9 0.6162
Memory 0.0657 1.66× 10−10 0.1536 0.0490 2.56 × 10− 2 0.0863
Symbol digit substitution − 0.1006 2.79 × 10−7 0.2816 − 0.0785 5.00 × 10− 2 0.1802
Reaction time 0.0390 4.79× 10− 4 0.0422 0.0509 3.68 × 10− 2 0.0692
Verbal-numerical reasoning − 0.1101 2.16 × 10− 21 0.3467 − 0.1390 2.88 × 10− 8 0.5495
Clinical and trait-related features
PHQ 0.0827 3.25×10−14 0.2218 −0.0259 4.20×10−1 0.0111
Neuroticism 0.0539 4.79× 10−19 0.3026 0.0055 6.82×10−1 0.0029
Abbreviations: GHQ, General Health Questionnaire; MDD, major depressive disorder; PHQ, Patient Health Questionnaire; PRS, polygenic risk score; SCZ,
schizophrenia; SFHS, Scottish Family Health Study. R2 represents estimate of variance in trait explained by polygene score in percentage. Significant
interactions are highlighted in bold.
Figure 2. Bar chart of percentage variance explained for distress and neuroticism in GS:SFHS and UK Biobank (UKB). GS:SFHS, Generation
Scotland: Scottish Family Health Study; MDD, major depressive disorder; PGRS, polygenic risk score; SCZ, schizophrenia.
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factor indicated a significant interaction between SCZ-PRS and
MDD case–control status for the digit symbol coding test. This test
is a measure of processing speed, which is known to be
significantly impaired in SCZ patients, even in relation to other
neuropsychological measures.52,53 Within GS:SFHS, significant
negative associations between SCZ-PRS and processing speed
were reported in both controls and the MDD cases. In other words,
the individuals in GS:SFHS with MDD demonstrated greater
deficits in tests of processing speed in those who had higher
genetic loading for SCZ versus those at low risk. However, the lack
of formal replication means these results should be viewed with
caution.
We are aware of one other recent large study using PRSs,
including those for SCZ, to determine potential subtypes within
MDD.12 This study took the approach of determining subgroup
classification based on symptom profiles (typical/atypical) and
then compared groups using various PRS measures. They reported
that typical MDD had a greater genetic overlap with PRS SCZ than
atypical MDD, which was more closely related to cardiometabolic
PRS such as body mass index and trigycerides.12 Although similar,
it is however difficult to make direct comparisons between this
and the current study, since we used the opposite approach of
categorizing according to PRS SCZ and then examined associa-
tions with features such as cognition, personality features and
psychological distress, which were not described in the Milaneschi
et al.12 study.
Limitations
Although this is a large and arguably well-powered study with
independent replication, there are important limitations that
should be considered. Of note is that the data used to derive
polygenic scores do not presently fully account for all heritability
attributable to common variation, nor do these measures reflect
the contribution of rare variation and copy-number variants. In
addition, the degree of variance explained by the SCZ PRS score
for these phenotypes is relatively modest (0.5–1%). It should be
considered, however, that they are consistent with other
previously reported figures of 0–2% for similar phenotypes and
in similarly unselected population-based cohorts, and that the
higher figures reported in the literature (7–18%) generally relate to
the phenotype of SCZ case–control status (see ref. 26).
Another limitation relates to consistency of testing between
these large data sets. Particularly relevant are the differences in
administration of the tests of processing speed. Within GS:SFHS, a
pen and paper version of the Digit Symbol Coding task from the
Wechsler Adult Intelligence Scale III was used, where participants
had a 2 min time limit to complete the task. In UKB, the format of
the task was a computerized version where the participant had to
click on the number that matched the symbol shown and the
participant had 1 min to complete the test. Importantly, there
were also fewer individuals included in the DSC assessments in
UKB (n= 7799 controls and n= 1767 MDD individuals) than for
other cognitive measures, and in relation to GS:SFHS (n= 16 566
controls and n = 2566 MDD individuals) as this test was conducted
at a follow-up assessment rather than at baseline.
The approach we have currently applied consisted of present-
ing two separate analyses for GS:SFHS and UKB, declaring
significance when both the studies reported findings with
Po0.05. However, we further note that a more stringent
approach would be to apply multiple comparison correction
within each cohort separately. Applying such a correction for the
summary cognitive measure and measures of clinical trait features,
the main interactions for distress and neuroticism remained
significant in both the cohorts (GS:HFHS, PFDR corrected = 0.0216,
PFDR corrected = 0.0059; in UKB PFDR corrected = 0.0024, PFDR corrected =
0.0342, for distress and neuroticism, respectively (FDR, false
discovery rate)).
In summary, we consider the main novel finding is not just the
significant relationship between PRS SCZ and neuroticism in
controls, but the lack of that clear relationship in MDD, inferring
heterogeneity. These findings are consistent with a model in
which genetic risk for schizophrenia predicts depressive traits in
the general population, but that neuroticism and psychological
distress may be less closely related to the aetiology of depression
on a background of high genetic risk for schizophrenia. This may
represent a somewhat causally distinct form of MDD more closely
related to SCZ. The study of the genetic basis of variation in such
measures is likely to further the understanding of mechanisms by
which SCZ genes affect neural function in the context of health
and depressive illness.
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